Handelsbanken Fonder AB Sells 26,695 Shares of Royalty Pharma plc (NASDAQ:RPRX)

Handelsbanken Fonder AB lowered its position in shares of Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 5.8% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 433,488 shares of the biopharmaceutical company's stock after selling 26,695 shares during the quarter. Handelsbanken Fonder AB owned 0.08% of Royalty Pharma worth $13,494,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Allworth Financial LP raised its holdings in shares of Royalty Pharma by 417.6% during the fourth quarter. Allworth Financial LP now owns 1,087 shares of the biopharmaceutical company's stock valued at $28,000 after acquiring an additional 877 shares during the period. MassMutual Private Wealth & Trust FSB raised its holdings in shares of Royalty Pharma by 76.4% during the first quarter. MassMutual Private Wealth & Trust FSB now owns 956 shares of the biopharmaceutical company's stock valued at $30,000 after acquiring an additional 414 shares during the period. Riverview Trust Co raised its holdings in shares of Royalty Pharma by 3,953.3% during the fourth quarter. Riverview Trust Co now owns 1,216 shares of the biopharmaceutical company's stock valued at $31,000 after acquiring an additional 1,186 shares during the period. Rakuten Securities Inc. raised its holdings in shares of Royalty Pharma by 160.5% during the fourth quarter. Rakuten Securities Inc. now owns 1,628 shares of the biopharmaceutical company's stock valued at $42,000 after acquiring an additional 1,003 shares during the period. Finally, Westpac Banking Corp acquired a new stake in shares of Royalty Pharma during the fourth quarter valued at approximately $53,000. Institutional investors and hedge funds own 54.35% of the company's stock.

Royalty Pharma Stock Down 1.2%

NASDAQ:RPRX traded down $0.43 during trading hours on Friday, reaching $34.84. The company's stock had a trading volume of 3,524,988 shares, compared to its average volume of 3,610,883. The company has a market cap of $19.59 billion, a price-to-earnings ratio of 24.03, a price-to-earnings-growth ratio of 2.31 and a beta of 0.48. Royalty Pharma plc has a one year low of $24.05 and a one year high of $35.38. The business's 50-day moving average is $32.82 and its 200-day moving average is $30.95. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.44 and a quick ratio of 1.44.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.99 by $0.07. The firm had revenue of $839.00 million during the quarter, compared to analysts' expectations of $724.69 million. Royalty Pharma had a net margin of 37.94% and a return on equity of 24.40%. Equities research analysts predict that Royalty Pharma plc will post 4.49 EPS for the current year.

Royalty Pharma Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Investors of record on Friday, May 16th were issued a dividend of $0.22 per share. This represents a $0.88 annualized dividend and a dividend yield of 2.53%. The ex-dividend date was Friday, May 16th. Royalty Pharma's dividend payout ratio is currently 47.57%.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on RPRX shares. Morgan Stanley began coverage on shares of Royalty Pharma in a report on Friday, May 16th. They set an "overweight" rating and a $51.00 price target on the stock. Citigroup reiterated a "buy" rating on shares of Royalty Pharma in a research note on Friday, March 28th. Finally, Wall Street Zen lowered shares of Royalty Pharma from a "buy" rating to a "hold" rating in a research note on Tuesday, May 20th. One research analyst has rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Buy" and an average target price of $47.33.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.